NEW YORK, July 30, 2019 /PRNewswire/ — Joseph R. Ficalora, President, Chief Executive Officer and a Director of New York Community Bancorp – the 25th largest bank holding company in the nation – has joined the Patient Innovations Advisory Board.
Under Mr. Ficalora’s leadership, the bank grew from a local savings bank to a regional banking powerhouse with 251 locations in five states.
Ken Greenberg, Patient Innovations Co-founder and President noted, “We are thrilled to have Joe Ficalora join our team. His business and financial acumen and desire for growth are a perfect fit and alignment with the PI mission.”
John M. Tabone, Chairman & CEO said, “It’s an honor and privilege to welcome Joe Ficalora to our Advisory Board. He represents an amazing addition to our fine team of healthcare leaders. Joe’s banking, business and growth skills – along with his strong commitment to community service – will help us steer Patient Innovations forward.”
Mr. Ficalora commented, “NYCB is a community bank committed to being a good neighbor. We’re here to serve our communities. The Patient Innovations OnTimeCare technology platform reduces endless waiting in doctors’ offices and helps make hospitals more efficient. This means greater access and a better patient experience for the communities we serve. Ultimately, this can slow the rising cost of healthcare. These are important goals that fit well with our mission to serve.”
See Mr. Ficalora’s bio here.
About Patient Innovations
Patient Innovations is converging technology, clinical insights and real-time provider and asset data to address the inefficiencies in patient access, healthcare delivery and compliance. Our interoperable RTLS platform manages content at scale and provides persisted datasets that drive optimal clinical workflows and insights that shape care decisions.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ficalora-joins-patient-innovations-advisory-board-300892702.html
SOURCE Patient Innovations
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the…
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…